Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic